Question 6: besides quantitative applications what else can hybrid assay technology do that will be important to future biotherapeutic development?
Question 5: what challenges do you experience when utilizing hybrid LBA/LC–MS assays in research and development? How do you avoid/overcome these?
Question 4: what questions can be answered by hybrid LBA/LC–MS assays over traditional bioanalytical techniques?
Question 3: how do you decide whether to use LBA or hybrid LBA/LC–MS assays in discovery and development?
Question 2: both LBA and LC–MS have their place in drug discovery and development. What is the advantage of using them as complimentary tools?
Question 1: could you briefly introduce yourself and your organization?
In this podcast, Mark Wrona (Principal Scientist at Waters Corporation; MA, USA) discusses his experience with HRMS and the current trends in the field of DMPK.
Bioanalysis Zone is proud to announce the 2019 Bioanalysis Outstanding Contribution Award winner – find out who has won this year’s award here!
Discover more about new μFLC technologies that are providing discovery bioanalytical scientists with an effective strategy for method development and optimization in this article from Bioanalysis.
In this article from Bioanalysis, the authors give their perspectives and findings in exploring a hybrid LBA/LC–MS as an orthogonal bioanalytical tool for clinical immunogenicity assessments.
